share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K:重大事件
美股SEC公告 ·  05/02 08:03

Moomoo AI 已提取核心信息

Mangoceuticals, Inc., a Texas-based company trading under the symbol MGRX on the Nasdaq Stock Market, has been granted a 180-day extension until October 24, 2024, to meet the Nasdaq's minimum bid price requirement. The company had previously been notified of non-compliance with Nasdaq's minimum bid price and stockholders' equity requirements. Mangoceuticals reported stockholders' equity of $1,354,821 in the quarter ended September 30, 2023, which was below the Nasdaq's minimum requirement of $2,500,000. However, following certain transactions, the company believes it has regained compliance with the stockholders' equity rule. The company has also been advised that failure to demonstrate compliance upon filing its next periodic report may lead to delisting. To address the minimum bid price requirement, Mangoceuticals may consider a reverse...Show More
Mangoceuticals, Inc., a Texas-based company trading under the symbol MGRX on the Nasdaq Stock Market, has been granted a 180-day extension until October 24, 2024, to meet the Nasdaq's minimum bid price requirement. The company had previously been notified of non-compliance with Nasdaq's minimum bid price and stockholders' equity requirements. Mangoceuticals reported stockholders' equity of $1,354,821 in the quarter ended September 30, 2023, which was below the Nasdaq's minimum requirement of $2,500,000. However, following certain transactions, the company believes it has regained compliance with the stockholders' equity rule. The company has also been advised that failure to demonstrate compliance upon filing its next periodic report may lead to delisting. To address the minimum bid price requirement, Mangoceuticals may consider a reverse stock split, which was previously approved by shareholders. The company's common stock will be subject to delisting if compliance is not regained within the extension period. Additionally, Mangoceuticals has corrected errors in a previously filed Certificate of Designations regarding its Series C Preferred Stock and has announced the date for its 2024 Annual Meeting of Stockholders.
总部位于德克萨斯州的Mangoceuticals, Inc. 是一家在纳斯达克股票市场上交易代码为MGRX的公司,已获准将期限延长180天至2024年10月24日,以满足纳斯达克的最低出价要求。该公司此前曾被告知不遵守纳斯达克的最低出价和股东权益要求。Mangoceuticals报告称,截至2023年9月30日的季度股东权益为1,354,821美元,低于纳斯达克规定的250万美元的最低要求。但是,在进行某些交易之后,该公司认为已经恢复了对股东权益规则的遵守。该公司还被告知,在提交下一次定期报告时未能证明其合规性可能会导致退市。为了满足最低出价要求,Mangoceuticals可能会考虑反向股票拆分,该拆分此前已获得股东批准。如果在延长期内没有恢复合规性,该公司的普通股将被退市。此外,Mangoceuticals更正了先前提交的有关其C系列优先股的指定证书中的错误,并宣布了其2024年年度股东大会的日期。
总部位于德克萨斯州的Mangoceuticals, Inc. 是一家在纳斯达克股票市场上交易代码为MGRX的公司,已获准将期限延长180天至2024年10月24日,以满足纳斯达克的最低出价要求。该公司此前曾被告知不遵守纳斯达克的最低出价和股东权益要求。Mangoceuticals报告称,截至2023年9月30日的季度股东权益为1,354,821美元,低于纳斯达克规定的250万美元的最低要求。但是,在进行某些交易之后,该公司认为已经恢复了对股东权益规则的遵守。该公司还被告知,在提交下一次定期报告时未能证明其合规性可能会导致退市。为了满足最低出价要求,Mangoceuticals可能会考虑反向股票拆分,该拆分此前已获得股东批准。如果在延长期内没有恢复合规性,该公司的普通股将被退市。此外,Mangoceuticals更正了先前提交的有关其C系列优先股的指定证书中的错误,并宣布了其2024年年度股东大会的日期。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息